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Abstract Background Pancreatitis is a potential major complication after endoscopic retrograde 
cholangiopancreatography (post-ERCP pancreatitis; PEP). Obesity has been associated with 
increased severity of acute pancreatitis. However, the correlation between obesity and PEP is 
controversial. Therefore, our study aimed to clarify the relationship between body mass index 
(BMI) and the incidence and severity of PEP.
Methods A retrospective cohort study was conducted to elucidate the relationship between BMI 
and PEP in all patients who underwent ERCP in a tertiary referral center between January 2009 
and October 2016. Patient characteristics and procedure details were collected. PEP was defined 
by consensus criteria. Multivariate logistic regression was used to determine the association 
between BMI and PEP.
Results The analysis included 2236 patients whose BMI was recorded and had adequate follow up 
(921 with BMI≥30 kg/m2, 1315 with BMI<30 kg/m2). PEP was diagnosed in 107 (4.8%) patients. 
PEP was seen in 49 obese patients (5.3%) and 58 non-obese patients (4.4%). In the univariate and 
multivariate analysis BMI≥30 kg/m2 was not associated with PEP (odds ratio 1.2, 95%CI 0.8-1.8; 
P=0.32). A subgroup analysis of different BMI subcategories found that BMI was not associated 
with the incidence or severity of PEP.
Conclusion In the largest study to date, neither obesity nor low body weight increased the 
incidence or severity of PEP.
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Introduction
Acute pancreatitis is a major complication after endoscopic 
retrograde cholangiopancreatography (ERCP). The incidence 
of post-ERCP pancreatitis (PEP) ranges from 1-9% in 
average-risk patients [1] and from 11-40% in high-risk 
patients, with a 0.1% mortality risk related to pancreatitis and 
an annual healthcare expenditure totaling $199 million in the 
United States [2-9].
Risk factors for PEP have been studied extensively and 
are classified into patient-  and procedure-related factors. 
Procedure-related risk factors include difficult or failed biliary 
cannulation, biliary sphincter balloon dilatation, pancreatic 
sphincterotomy and pancreatic duct injection. Patient-related 
factors such as young age, female sex, suspected sphincter of 
Oddi dysfunction, history of recurrent pancreatitis, history of 
prior PEP, and absence of chronic pancreatitis have all been 
shown to increase the likelihood of PEP [10-13]. Identification 
of these risk factors has allowed clinicians to risk-stratify 
patients and determine if PEP prophylaxis is necessary.
Studies have shown that obesity may contribute to the 
incidence, severity and mortality of acute pancreatitis [14-17]. 
This is presumably due to the chronic low-grade inflammatory 
state that has been observed in obese patients [18]. Obesity 
is also associated with decreased levels of adiponectin, an 
anti-inflammatory adipokine that may be a protective factor 
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for acute pancreatitis [19]. Additionally, peripancreatic and 
retroperitoneal fat deposits could be susceptible to fat necrosis 
and increase the risk of additional local complications of acute 
pancreatitis, such as abscesses and pseudocysts [15].
The correlation between obesity and the incidence and 
severity of PEP has not yet been elucidated. A larger retrospective 
study of 964 patients by Deenadayalu et al showed that rates of 
PEP did not differ between patients with a body mass index 
(BMI)≥30  kg/m2 and those with BMI<30  kg/m2  (12.5% vs. 
16.4%, respectively, P=0.14).
In contrast, Cotton et al showed that obesity is associated 
with post-ERCP complications, including PEP [20]. To 
complicate things further, a recent retrospective study of 
583 patients by Fujisawa et al demonstrated that obese patients 
(BMI≥30 kg/m2) had a significantly higher rate of PEP compared 
to overweight (BMI 25-30 kg/m2), normal-weight (BMI 18.5-
25  kg/m2), and underweight (BMI<18.5  kg/m2) patients. 
However, one of the limitation of the Fujisawa et al study that 
only 20  patients were obese [21]. Furthermore, Kumar et al 
performed a national database analysis that was suggestive of a 
positive correlation between obesity and PEP (odds ratio [OR] 
1.55, 95% confidence interval [CI] 1.25-1.92) [24].
While numerous studies have examined the relationship 
between obesity and acute pancreatitis, far less is known about 
low BMI and acute pancreatitis, let alone PEP. Fujisawa et al 
reported that underweight patients (BMI<18.5) had higher 
rates of PEP compared to normal-weight individuals (BMI 
18.5-25). There was no difference in the severity of PEP between 
normal- and underweight patients [19]. In comparison, a study 
by Deenadayalu et al examined the incidence of PEP in patients 
with BMI<20 and found no increase in PEP [21]. In this study, 
we aimed to better clarify the relationship between BMI and 
the incidence and severity of PEP.
Patients and methods
After approval by the University and Medical Center 
Institutional Review Board at East Carolina University/
Vidant Medical Center, we conducted a retrospective study 
of all ERCPs performed at the Center from January 2009 to 
October 2016. The study included all patients who underwent 
diagnostic or therapeutic ERCP within the study period.
The procedures were performed by 4 experienced 
endoscopists. All patients underwent ERCP with a standard 
duodenoscope (JF 260 or 260V; Olympus Optical Co., Ltd., 
Tokyo, Japan). Patient characteristics and procedural details 
were collected. Patients noted to have had acute pancreatitis 
within 72 h before the procedure were excluded from the study.
We reviewed patient demographic information, relevant 
medical history and home medications. All available laboratory 
blood work, pre-  and post-procedure imaging studies, and 
follow-up documentation were also reviewed. Procedure 
details, including sphincterotomy, biopsy, stent placement/
removal, cannulation of the common bile duct, cannulation of 
the main pancreatic duct, cholangiogram, and pancreatogram 
were noted. Type and size of any endobiliary stent were noted, 
along with information on other interventions performed 
during the ERCP.
Follow up
All the documented complications of ERCP in the electronic 
health record from subsequent admissions, emergency room or 
follow-up clinic visits, nurse’s post-procedure phone calls and 
notifications of admission to another hospital or emergency 
room were reviewed. Complications were collected, including 
post-ERCP pancreatitis, end-organ damage, pancreatic 
necrosis, and death.
Definitions
BMI was classified according to the World Health 
Organization’s definition: underweight, BMI<18.5  kg/m2; 
normal weight, BMI 18.5-25 kg/m2; obese, BMI 30-40 kg/m2; 
morbidly obese, BMI≥40 kg/m2.
PEP was defined as new-onset or worsening abdominal 
pain causing an unplanned admission following an outpatient 
ERCP, or prolongation of a hospital stay following an ERCP. 
This diagnosis was associated with an increase in serum 
lipase or amylase levels to at least 3-fold greater than normal 
approximately 24 h after the procedure [15].
The severity of PEP was graded according to the revised 
Atlanta classification: mild, no evidence of organ failure or local 
or systemic complications; moderate, transient organ failure, or 
local or systemic complications in the absence of persistent organ 
failure; or severe, persistent organ failure or pancreatic necrosis. 
High-risk ERCP was defined based on prospectively validated 
patient and procedure-related independent risk factors [16-20].
Outcomes
The primary outcome of interest was the incidence of PEP 
in consecutive ERCPs. The secondary outcome of interest was 
the severity of PEP.
Statistical analysis
Continuous variables were evaluated using Student’s t-test 
and categorical variables using Fisher’s exact test. Patients with 
BMI≥30 kg/m2 were compared with those with BMI <30 kg/m2. 
Univariate logistic regression analysis of clinical and procedural 
factors associated with PEP was then conducted, with PEP 
as the dependent variable and the following independent 
variables: age, sex, BMI, rectal indomethacin administration, 
procedure indication, bilirubin level, prior pancreatitis, prior 
PEP, cannulation of pancreatic duct with contrast, pancreatic or 
biliary sphincterotomy, difficult cannulation, brush/cytology, 
biopsy, stent placement, balloon dilation and stone extraction. 
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All mutually exclusive variables associated with PEP (P<0.1) 
in the univariate analysis were included in the multivariate 
logistic regression model. Statistical analysis was carried out 
using JMP software (v10; SAS Institute Inc., Cary, NC).
Results
A total of 2236 patients whose BMI was recorded and who 
had adequate follow up were included in the final analysis. 
The average patient age was 60±18 years; 1247 (56%) patients 
were female, and 991 (44%) were male. The average BMI was 
29±8 (kg/m2). Procedure risk factors did not differ between the 
2 groups.
Study outcome
Overall, 17% of the patients who underwent ERCP were 
high-risk for PEP. PEP was diagnosed in 107 (4.8%) patients. In 
total, 921 patients had BMI≥30 kg/m2 while 1315 patients had 
BMI<30 kg/m2. There was no statistically significant difference 
in the procedure or patients’ risk factors between the patients 
in the low- (<30 kg/m2) and high-BMI (≥30 kg/m2) groups. Of 
the 921  patients with BMI≥30, 49 were diagnosed with PEP 
(5.3%). In comparison, 58 patients (4.4%) were diagnosed with 
PEP of the 1317 patients with BMI<30 kg/m2 (odds ratio [OR] 
1.2, 95%CI 0.82-1.8; P=0.32). There was no difference in the 
incidence of PEP in BMI subgroups (Fig. 1).
In the univariate analysis, the following factors were 
associated with PEP: female aged <40  years, biliary 
sphincterotomy, pancreatic sphincterotomy, cannulation of 
the main pancreatic duct, contrast injection into the pancreatic 
duct (limited and complete pancreatogram), difficult 
cannulation, failed pancreatic duct stent placement, and a 
history of recurrent acute pancreatitis (Table 1).
In the multivariate model, female sex and <40 years of age, 
biliary sphincterotomy, pancreatic sphincterotomy, contrast 
injection into the pancreatic duct (limited and complete 
pancreatogram), difficult cannulation, and failed pancreatic 
duct stent placement were associated with PEP. However, 
BMI≥30 did not impact the incidence of PEP (OR 1.1, 95%CI 
0.75-1.8; P=0.48) (Table 2). Likewise, there was no difference in 
the incidence of PEP in the subgroup analysis of different BMI 
categories (Table 3).
Severity of PEP
Seven patients were diagnosed with moderately severe 
pancreatitis according to the revised Atlanta classification: one 
in the underweight group, two in the normal BMI group, three 
in the overweight group and one in the morbidly obese group.
Nine patients were diagnosed with severe pancreatitis: 1 in 
the underweight group, 2 in the normal BMI group, 1 in the 
overweight group, 3 in the obese group, and 2 in the morbidly 
obese group. Three of the 9 patients died within 30 days: 1 in 
the morbidly obese group, 1 in the obese group, and 1 in the 
normal BMI group.
Discussion
Results from our study indicated that increased BMI 
(≥30  kg/m2) does not increase the risk of PEP. Furthermore, 
different subcategories of BMI, including underweight, 
overweight, obese and morbidly obese, are not associated 
with a different incidence of PEP compared to normal-weight 
patients. Our results were consistent with those of Deenadayalu 
et al [21].
Likewise, our study clearly demonstrates that an increase 
or decrease in BMI does not impact the severity of PEP. 
We used the revised Atlanta classification to categorize the 
severity of PEP [22]. Persistent organ failure and necrosis were 
distributed equally between the obese and non-obese patients. 
Our results differ from observational studies that suggest 
obesity increases the incidence, severity, and mortality of acute 


















(BMI 25 - 30)
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(BMI >40)
N of patients with PEP (n=102) Total
Figure 1 The number of PEP in each of the BMI subgroups
PEP, post-endoscopic retrograde cholangiopancreatography pancreatitis; BMI, body mass index
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in the etiology and mechanism of acute pancreatitis (such 
as alcohol or hypertrygliceridemia) and PEP. It has been 
suggested that local injury to the papilla from instrumentation, 
sphincterotomy or forceful and repetitive injection of contrast 
causes papillary edema or spasm. This is thought to result 
in ductal hypertension followed by reduced pancreatic duct 
drainage. The poor drainage initiates an inflammatory cascade, 
promoting intraluminal activation of proteolytic enzymes and 
autodigestion of the pancreas. Significant release of cytokines 
(interleukin -1, -6, and -8) results in a systemic inflammatory 
response with multiorgan involvement [8,23].
There are several strengths to our study, including the large 
sample size. Given the relatively low incidence of PEP, a large 
sample size is imperative for the study to have enough power 
to detect differences in PEP between various BMI groups. To 
date, this is the largest retrospective study to investigate the 
relationship between PEP and BMI. Another strength of our 
study is the comprehensive dataset, which includes all possible 
confounders and the use of univariate and multivariate analyses 
to accurately define the impact of BMI on PEP.
The study has a few notable limitations. First, BMI was used 
as a surrogate for obesity. BMI is imperfect, as it uses weight 
rather than body composition and therefore cannot distinguish 
between adiposity and increased muscle mass. Second, while 
Table 1 Incidence of PEP according to risk factors
Risk factors PEP n (%) P OR (95%CI)
Female sex 68/1246 (5.5) 0.09 0.7 (0.47-1.1)
Female <40 years 19/257 (7.4) 0.05* 1.7 (1.0-2.9)
Body mass index (BMI) ≥ 30 49/921 (5.3) 0.32 1.2 (0.8-1.8)
Normal bilirubin 51/1171 (4.4) 0.31 1.2 (0.8-1.8)
History of PEP 3/58 (5.2) 0.89 1.0 (0.3-3.5)
History of recurrent pancreatitis 11/121 (9) 0.002* 2.6 (1.3-5.1)
Difficult cannulation 48/500 (9.6) 0.0001* 5.6 (3.7-8.6)
Biliary sphincterotomy 74/1064 (7) 0.000* 2.5 (1.7-3.9)
Biliary stent insertion 41/787 (5.2) 0.49 1.2 (0.8-1.6)
Cannulation of MPD 57/658 (8.7) 0.000* 2.9 (2-4)
Cannulation of MPD with wire only 17/251 (6.7) 0.14 1.5 (0.9-2.6)
Limited pancreatogram 19/144 (13.2) 0.000* 3.5 (2.0-5.9)
Complete pancreatogram 20/197 (10.2 ) 0.001* 2.5 (1.5-4.2)
Pancreatic sphincterotomy 12/67 (18) 0.000* 4.8 (2.5-9.2)
Pancreatic duct dilatation 3/56 (5.4) 0.87 1.1 (0.34-3.6)
Failed PDS placement 8/17 (47) 0.0001* 19 (7.2-50)
EUS FNA of the pancreas 12/161 (7.5) 0.12 1.3 (0.9-3.1)
*P value <0.05
ERCP, endoscopic retrograde cholangiopancreatography; PEP, post-ERCP pancreatitis; OR, odds ratio; CI, confidence interval; BMI, body mass index; MPD, main 
pancreatic duct; PDS, pancreatic duct stent; EUS FNA, endoscopic ultrasound fine-needle aspiration 
Table 2 Factors associated with PEP, multivariate analysis
Factors OR (95%CI) P
Female <40 years 1.8 (1.0-3.1) 0.04*
Cannulation of pancreatic duct, 
limited pancreatogram
3.5 (1.8-6.0) 0.001*
Cannulation of pancreatic duct, 
complete pancreatogram
2.6 (1.3-4.8) 0.001*
Difficult cannulation 2.6 (1.7- 4) 0.001 *
Biliary sphincterotomy 3 (1.9-4.7) 0.001*
Pancreatic sphincterotomy 2.6 (1.1-5.6) 0.03*
Failed pancreatic duct stent placement 13 (4.0-41) 0.001*
Recurrent pancreatitis 1.4 (0.7-3) 0.29
BMI ≥30 kg/m2 1.2 (0.8-1.8) 0.49
*P<0.05
ERCP, endoscopic retrograde cholangiopancreatography; PEP, post-ERCP 
pancreatitis; OR, odds ratio; CI, confidence interval; BMI, body mass index
Table 3 Incidence of PEP by BMI groups




P-value vs. normal 
weight
Underweight (BMI <18.5) 6/116 (4.6) 1 (0.4-2.6) P=0.8
Normal weight (18.5-25) 27/579 (4.7)
Overweight (BMI 25-30) 25/620 (4) 0.9 (0.5-1.4) P=0.6
Obese (BMI 30-40) 34/697 (4.8) 1.0 (0.6-1.7) P=0.85
Morbidly obese (BMI >40) 15/224 (7) 1.4 (0.8-2.6) P=0.26
ERCP, endoscopic retrograde cholangiopancreatography; PEP, post-ERCP 
pancreatitis; BMI, body mass index; RR, risk ratio; CI, confidence interval
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Summary Box
What is already known:
•	 Acute	pancreatitis	is	a	major	complication	following	
endoscopic retrograde cholangiopancreatography 
(ERCP)
•	 Procedure-related	 risk	 factors	 for	 post-ERCP	
pancreatitis (PEP) include difficult or failed biliary 
cannulation, biliary sphincter balloon dilatation, 
pancreatic sphincterotomy, and pancreatic duct 
injection
•	 Patient-related	 factors	 include	 young	 age,	 female	
sex, suspected sphincter of Oddi dysfunction, 
history of recurrent pancreatitis, history of prior 
PEP, and absence of chronic pancreatitis
What the new findings are:
•	 Obesity	does	not	increase	the	incidence	or	severity	
of PEP
•	 Low	 body	 mass	 index	 does	 not	 impact	 the	
incidence or severity of PEP
our study had a large sample size, it was retrospective in design 
and was thus susceptible to confounding. We attempted to 
adjust for this using univariate and multivariate analysis to 
detect any confounding variables.
In conclusion, our study showed no correlation between 
obesity and the incidence or severity of PEP. Likewise, patients 
classified as underweight did not have a higher incidence or 
severity of PEP. Future studies on this topic should ideally be 
performed prospectively to minimize bias and should use other 
measures of body composition to better evaluate obesity status.
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